

James J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/837368/publications.pdf>

Version: 2024-02-01

27
papers

13,375
citations

687363

13
h-index

677142

22
g-index

27
all docs

27
docs citations

27
times ranked

19257
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. <i>Clinical Epigenetics</i> , 2022, 14, 3.	4.1	26
2	Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 99-99.	1.6	8
3	NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3569-3569.	1.6	0
4	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 643-654.	2.3	1
5	The UPMC Hillman Cancer Center Approach to the Management of Colorectal Cancer During the COVID-19 Pandemic Era. <i>Clinical Colorectal Cancer</i> , 2020, 19, 146-148.	2.3	1
6	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
7	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	4.1	19
8	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 2450-2458.	5.1	5
9	What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 175-183.	0.5	0
10	ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 255-257.	2.3	12
11	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 258-273.	2.3	41
12	Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). <i>Clinical Colorectal Cancer</i> , 2017, 16, 85-92.	2.3	14
13	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
14	Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On. <i>Journal of Oncology Practice</i> , 2017, 13, 245-246.	2.5	14
15	Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3003-3003.	1.6	69
16	Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3054-3054.	1.6	24
17	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017, 35, 519-519.	1.6	49
18	Therapeutic drug monitoring of 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 447-464.	2.3	149

#	ARTICLE	IF	CITATIONS
19	Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 727-733.	2.3	2
20	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	27.0	7,696
21	KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1102-1111.	0.5	43
22	Pharmacokinetically Guided Dose Adjustment of 5-FU—A Critical Element Toward Personalized Medicine. <i>Clinical Colorectal Cancer</i> , 2014, 13, 1-2.	2.3	5
23	The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 395-402.	0.5	4
24	Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 135-144.	2.3	27
25	Oncotype DX for Colon Cancer: Are We Ready for Prime Time in Personalized Medicine?. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 312-316.	0.5	0
26	Personalized medicine in the adjuvant chemotherapy of stage II colon cancer—are we there yet?. <i>Oncology</i> , 2013, 27, 754, 756-8.	0.5	0
27	Giant Hydronephrosis; One Stage Nephrectomy. <i>Journal of Urology</i> , 1954, 72, 130-132.	0.4	3